Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G W Moran

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Alimentary Pharmacology & Therapeutics|December 17, 2013
Letter: dermatological complications with therapy for inflammatory bowel disease--authors' replyS Ghosh, G W Moran
Inflammatory Bowel Diseases|March 26, 2014
Reply to MendallG W Moran, Subrata Ghosh
Diagnostic and Therapeutic Endoscopy|June 24, 2009
Direct Percutaneous Endoscopic Jejunostomy: High Completion Rates with Selective Use of a Long Drainage Access NeedleG W Moran, N C Fisher
Inflammatory Bowel Diseases|September 26, 2008
Do non-immune cells have a role in IBD?Y R Mahida, G W Moran
Inflammatory Bowel Diseases|September 18, 2009
Plasma chromogranin A in patients with inflammatory bowel disease: a possible explanationG W Moran, J T McLaughlin
Regulatory Peptides|July 20, 2012
GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrierG W Moran, C O'Neill, J T McLaughlin
Alimentary Pharmacology & Therapeutics|December 21, 2012
Commentary: a comparison of glucagon-like peptides 1 and 2G W Moran, S Lal, J T McLaughlin
Gut|August 23, 2008
Ulcers and the colon: keep an open mindG W Moran, R Hejmadi, E Campbell, et al.
Regulatory Peptides|May 8, 2012
Dipeptidyl peptidase-4 expression is reduced in Crohn's diseaseG W Moran, C O'Neill, P Padfield, et al.
Expert Opinion on Biological Therapy|June 25, 2016
Ustekinumab: a novel therapeutic option in Crohn's diseaseE G Simon, S Samuel, S Ghosh, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Alimentary Pharmacology & Therapeutics|December 17, 2013
Letter: dermatological complications with therapy for inflammatory bowel disease--authors' replyS Ghosh, G W Moran
Inflammatory Bowel Diseases|March 26, 2014
Reply to MendallG W Moran, Subrata Ghosh
Diagnostic and Therapeutic Endoscopy|June 24, 2009
Direct Percutaneous Endoscopic Jejunostomy: High Completion Rates with Selective Use of a Long Drainage Access NeedleG W Moran, N C Fisher
Inflammatory Bowel Diseases|September 26, 2008
Do non-immune cells have a role in IBD?Y R Mahida, G W Moran
Inflammatory Bowel Diseases|September 18, 2009
Plasma chromogranin A in patients with inflammatory bowel disease: a possible explanationG W Moran, J T McLaughlin
Regulatory Peptides|July 20, 2012
GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrierG W Moran, C O'Neill, J T McLaughlin
Alimentary Pharmacology & Therapeutics|December 21, 2012
Commentary: a comparison of glucagon-like peptides 1 and 2G W Moran, S Lal, J T McLaughlin
Gut|August 23, 2008
Ulcers and the colon: keep an open mindG W Moran, R Hejmadi, E Campbell, et al.
Regulatory Peptides|May 8, 2012
Dipeptidyl peptidase-4 expression is reduced in Crohn's diseaseG W Moran, C O'Neill, P Padfield, et al.
Expert Opinion on Biological Therapy|June 25, 2016
Ustekinumab: a novel therapeutic option in Crohn's diseaseE G Simon, S Samuel, S Ghosh, et al.
Pageof 2